.Nature Medicine, Published online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA authorization after a damaging trial, which highlights the many difficulties and also obstacles of medicine progression in this particular setting.